A Retrospective Study on the Factors of Drug-coated Balloon Restenosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

5000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-01

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to analyze potential factors post paclitaxel drug-coated balloon angioplasty in patients with Denovo large vessels disease. It includes imaging endpoints and clinical event endpoints. Over 5000 patients are expected to be enrolled.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Constrained Balloon Combined With Drug-coated Balloon Angioplasty for Femoropopliteal Lesion

NCT05894460

Peripheral Arterial Disease

UNKNOWN

Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity

NCT05158257

Atherosclerosis Ischemia

UNKNOWN NA

Drug-Eluting Balloon Registry in Routine Clinical Practice

NCT02038660

Coronary Artery Disease Angioplasty, Balloon

RECRUITING

Drug-coated Balloon Angioplasty for Patients With Symptomatic Vertebral Artery Stenosis

NCT03504657

Vertebral Artery Stenosis

UNKNOWN PHASE2

Treatment of Complex Femoropopliteal Artery Lesions Using Drug-coated PTA Balloon

NCT05616520

Peripheral Arterial Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a retrospective analysis that retrospectively reviewed over approximately 5000 patients with de novo-large-vessel disease who underwent paclitaxel drug-coated balloon angioplasty. The study endpoints include cardiovascular adverse events at 1 year (cardiovascular death, cardiovascular events) and coronary angiographic outcomes (primarily late lumen loss, restenosis rate). It primarily focuses on differences in baseline characteristics, lesion features, intracavitary imaging characteristics(Including OCT, IVUS), hemodynamic parameter，and procedural approaches among patients. Over 5000 patients are expected to be enrolled.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age:

18 years and older.
* Diagnosis:

Diagnosed with coronary artery disease with native large vessel lesions confirmed by coronary angiography.

* Treatment Plan:

Scheduled to receive paclitaxel drug-coated balloon angioplasty.

* Informed Consent:

Patients have been fully informed about the nature and purpose of the study, and have voluntarily agreed to participate, with signed informed consent.

* Physiological Status:

Cardiac function classified as NYHA I-III.

Exclusion Criteria

* Allergy History:

Known allergies to paclitaxel or any materials used in angioplasty (e.g., contrast agents).

* Severe Complications:

Uncontrolled hypertension (systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg).

* Other Medical Conditions:

Active bleeding or clotting disorders.

* Other serious diseases with a life expectancy of less than 1 year (e.g., advanced cancer).
* Pregnancy or Nursing: Women who are currently pregnant or breastfeeding.
* Participation in Other Studies: Currently participating in other clinical trials that might affect the results of this study.
* Psychological or Behavioral Factors: History of psychiatric or behavioral disorders that could interfere with adherence to study protocols, or communication barriers that prevent understanding of study requirements.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No